# Nurix Therapeutics Reports $549.8M Q3 Net Income on Roche Deal and Advances Phase 3 Cancer Trial

- URL: https://stocks.freetheai.org/news/nurix-therapeutics-reports-549-8m-q3-net-income-on-roche-deal-and-advances-phase-307d17
- Published: 2026-10-12T20:05:00Z
- Category: earnings; sentiment: bullish; impact: high
- Symbols: [NASDAQ:NRIX](https://stocks.freetheai.org/symbols/NASDAQ-NRIX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Nurix Therapeutics, Inc. (NRIX) reported fiscal third-quarter net income of $549.8 million, or $4.73 per diluted share, turning profitable from a net loss of $86.4 million in the same period last year. Total revenue surged to $673.1 million for the quarter ended August 31, 2026, driven primarily by $653.2 million in license revenue generated after closing a major global collaboration agreement with Roche.

The influx of capital increased cash, cash equivalents, and marketable securities for Nurix Therapeutics, Inc. (NRIX) to $1.1 billion. Company leadership noted that this balance extends its operational funding runway into the second half of 2029. The expanded balance sheet provides financial runway as the drugmaker advances its targeted protein degradation programs in oncology, immunology, and neurology.

Looking ahead, clinical developments remain a key focal point for investors. The company dosed its first patient in the Phase 3 DAYBreak CLL-306 trial, comparing lead drug candidate bexobrutideg against pirtobrutinib for patients with chronic lymphocytic leukemia. Meanwhile, recruitment has begun for combination study cohorts, and expansion trials are progressing across four solid tumor indications for candidate NX-1607.

## Key points

- Nurix Therapeutics generated $673.1 million in Q3 revenue and $549.8 million in net income, largely due to license revenue from Roche.
- Total cash and marketable securities rose to $1.1 billion, providing funding runway into the second half of 2029.
- The company dosed the first patient in its Phase 3 DAYBreak CLL-306 trial evaluating bexobrutideg in leukemia patients.
- Nurix discontinued development of candidate NX-2127 to focus on its prioritized oncology portfolio.

## Questions and answers

### What were Nurix Therapeutics Q3 2026 financial results?

Nurix Therapeutics reported Q3 2026 revenue of $673.1 million and net income of $549.8 million, or $4.73 per diluted share, driven by upfront licensing revenue from its Roche collaboration.

### How long is Nurix Therapeutics cash runway?

With $1.1 billion in cash, cash equivalents, and marketable securities as of August 31, 2026, Nurix Therapeutics expects its financial runway to last into the second half of 2029.

### What is the status of Nurix Therapeutics bexobrutideg trial?

Nurix Therapeutics has dosed the first patient in its registrational Phase 3 DAYBreak CLL-306 trial, which compares bexobrutideg with pirtobrutinib in patients with relapsed or refractory CLL/SLL.